121 results about "Need treatment" patented technology

The invention of the current disclosure includes methods and compositions useful for producing personalized cancer immunotherapies which target tumor-associated neoepitopes. Also included are methods for treating cancer in subjects in need thereof.

The invention provides a medical bed and a radiotherapy system. The medical bed comprises a main frame body, a plate assembly, a pitching rotating assembly and a horizontal rotating assembly, the pitching rotating assembly and the horizontal rotating assembly are both connected between the main frame body and the plate assembly, the pitching rotating assembly drives the plate assembly to rotate in a vertical plane along a first axis, and the horizontal rotating assembly drives the plate assembly to rotate in a horizontal plane along a second axis. The second axis and the first axis satisfy a vertical condition and intersect with each other. The plate assembly rotates around the same point in the vertical plane and the horizontal plane, so that a target area needing to be treated can be adjusted better and more pertinently, mutual influence during adjustment of different dimensions is avoided, and the positioning process is simpler and more efficient. The treatment efficiency is higher, the placement position is more accurate, and the treatment effect can be better guaranteed.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

In neonates or infants, the system identifies Neonatal Abstinence Syndrome (NAS) and in adult patients the system monitors for and identifies withdrawal and / or relapse symptoms. The system can be used for NAS babies in hospitals as well as in the home for adults. The system obtains biosensor or behavioral information about a patient from a wearable device on the patient and makes a determinative recommendation based on algorithm driven calculations and takes appropriate action based on its evaluation. The biosensor and behavioral information are collected by way of a wearable device, high precision cameras, multi pitch microphones over progressive periods of time. When the data is indicative of a need for treatment because the patient is exhibiting symptoms or indicating relapse traits, this information is sent to the system where an AI module further predicts and recommends a delivery of treatment for the patient.

Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.

Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer. Also disclosed herein is a method of treating brain cancer in a subject in need thereof, comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is brain-penetrating.

Treatment system (100) for treating workpieces (102), having a treatment region (108) for receiving workpieces (102) to be treated, and a plurality of operating devices (130) for performing one or more operations on the workpieces (102) to be treated.

Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.

A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.

Provided herein are methods of treating or preventing cancer in a subject in need thereof, the methods comprise administering to the subject in need thereof (a) one or more nucleic acids encoding an elephant p53 protein, an elephant LIF protein, and / or combinations thereof, or (b) one or more elephant p53 proteins, elephant LIF proteins, and / or combinations thereof. Also provided are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and (a) one or more nucleic acids encoding an elephant p53 protein, an elephant LIF protein, and / or combinations thereof, or (b) one or more elephant p53 proteins, elephant LIF proteins, and / or combinations thereof.

To provide treatment of cancers with GM-CSF antagonists.SOLUTION: The present invention provides, among other things, a method of treating cancer comprising administering a GM-CSF antagonist to a patient in need of treatment, where the administration of the GM-CSF antagonist results in inhibition of an immunosuppressive activity of myeloid-derived suppressor cells (MDSCs). The present invention also provides, among other things, a method of inhibiting immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) in a patient suffering from cancer, comprising administering a GM-CSF antagonist to the patient.SELECTED DRAWING: None

Described herein is a novel method of treating cancer in a patient in need thereof, comprising administering a therapeutically effective amount of SARS-CoV-2 Spike 51 polypeptide.

To provide a polypeptide complex that exhibits cytotoxicity to a target cancer cell by T cells, a method for preparing the polypeptide, a cytotoxicity-inducing therapeutic agent comprising the polypeptide complex as an effective ingredient, as well as a pharmaceutical composition including the cytotoxicity-inducing therapeutic agent as an effective ingredient for treating or preventing various cancers or a therapeutic method using the pharmaceutical composition.SOLUTION: The invention provides a polypeptide complex which comprises: (1) an antigen-binding domain; (2) a domain comprising an Fc region with reduced Fcγ receptor-binding activity; and (3) a T cell receptor complex-binding domain. The invention also provides: a cell comprising the vector comprising the polynucleotide encoding the polypeptide complex; a method for preparing the polypeptide complex, comprising culturing the cell to harvest the polypeptide complex from the culture supernatant; a cytotoxicity-inducing therapeutic agent comprising the polypeptide complex as an effective ingredient; and a treating method comprising administering the therapeutic agent to a patient in need thereof.SELECTED DRAWING: None

The present disclosure describes methods of treating conditions such as trigeminal neuralgia and pain related thereto. The methods of the present disclosure may include administering to a patient in need thereof a therapeutically effective amount of Trimeprazine or a pharmaceutically acceptable salt thereof, thereby treating the patient. The methods may include reducing a patient's pain as determined by patient-reported or clinician-delivered outcome assessments.

To provide a method for treating a subject in need of treatment, the method comprising administering a large agent (for example, a biologically active large agent, such as a biologic therapeutic, for example, botulinum toxin) to the subject.SOLUTION: A method of treating a subject in need of treatment is provided, the method comprising a step of administering, in combination with microneedle skin conditioning (MSC), a plurality of doses of a composition that delivers a large agent having a molecular weight of 100,000 Da or greater to a site on skin of the subject according to a dosing regimen in which at least two successive doses are separated from one another by a time period of at least one month.SELECTED DRAWING: None

The present invention relates to combination therapies for treating cancers associated with genetic alterations in the MAPK pathway and / or EGFR. In particular, the present invention relates to a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of an SOS1 inhibitor and a MEK inhibitor, pharmaceutical compositions comprising such compositions, kits comprising such compositions, and methods of use thereof.

To provide a method of treating relapsed or refractory large B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, after two or more lines of systemic therapy.SOLUTION: In one aspect, provided is a method of treating relapsed or refractory large B-cell lymphoma in a patient, after two or more lines of systemic therapy, the method comprising: (a) administering a CD19-directed genetically modified autologous T-cell immunotherapy to a patient in need of treatment; and (b) monitoring the patient following the infusion for signs and symptoms of adverse reactions.SELECTED DRAWING: None

Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.

Methods and compositions disclosed herein generally relate to compositions and methods for suppressing hematopoietic stem and progenitor cells (HSPCs) and the treatment of diseases or disorders involving UBE2N, such as cancers, including disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) and chronic inflammatory disorders. Particular aspects relate to treating, e.g. acute myelomonocytic leukemia (AML-M4) and acute monocytic leukemia (AML-M5). Particular aspects of the invention relate to determining an individual in need of treatment who can be treated with a UBE2N inhibitor, such as an individual having AML-M4 and / or AML-M5. The invention further relates to using a UBE2N inhibitor to treat a disease or disorder characterized by malignant hematopoietic cells, as well as other cancers, and chronic inflammatory disorders, and as immune checkpoint regulators.

The present invention discloses a method, device and radiotherapy equipment for safety monitoring of a radiotherapy room. The method comprises the following contents: obtaining the current cumulative number of people in the radiotherapy room M through an entrance monitoring device arranged at the entrance of the radiotherapy room and an exit monitoring device arranged at the exit of the radiotherapy room; obtaining the current number of people in the radiotherapy room N through an entrance monitoring device arranged at the entrance of the radiotherapy room, an exit monitoring device arranged at the exit of the radiotherapy room and an internal monitoring device arranged in the radiotherapy room; obtaining N and M, and comprehensively judging whether there are patients in the radiotherapy room who need treatment. The present invention can effectively and intelligently monitor automatically, prevent the occurrence of misirradiation, and improve safety performance.

To provide PARP1 inhibitors and uses thereof.SOLUTION: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising the inhibitors. Subject compounds and compositions are useful for the treatment of cancer. Also disclosed herein is a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and a pharmaceutically acceptable excipient. A method of treating a cancer that is present in the brain in a subject in need thereof comprises administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.SELECTED DRAWING: None

The present invention relates to compositions comprising a combination of PI3K-ALPHA and MTOR inhibitors and methods of combination therapy for administering to subjects in need thereof for the treatment of solid tumor cancers.

Provided are pharmaceutical compositions for treating cancer patients. The pharmaceutical compositions include a combination of compounds inhibiting PTP1 b activity and chemotherapeutic agents. The PTP 1 b inhibitors in such pharmaceutical compositions can include a small molecule such as an anti-sense inhibitor, an allosteric / reversible inhibitor, and / or a permanent / chemical modification inhibitor. Methods of treating subjects are also provided. Such treatment methods include administering to a subject in need of treatment a pharmaceutical composition including one or more compounds inhibiting PTP1b activity and one or more chemotherapeutic agents. Also provided herein are methods of restoring an anti-tumor immune response in a subject receiving chemotherapy, including administering to the subject a PTP 1 b inhibitor prior to, during and / or after receiving a chemotherapeutic agent, whereby an anti-tumor immune response in the subject is restored and / or enhanced.

The present disclosure provides a method for treating major depressive disorder in a human patient, the patient being identified as positive for a biomarker signature. The method comprises administering an effective amount of aticaplant or a pharma- ceutically acceptable salt thereof to a patient in need of treatment for major depressive disorder. In some embodiments, the patient has had an inadequate response to other antidepressant therapy prior to treatment with aticaplant. In other embodiments, the other antidepressant therapy includes a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

In some embodiments, the present disclosure provides methods of treating a cancer in a subject in need thereof, wherein the cancer is selected from pancreatic cancer, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell cancer (HNSCC) comprising administering to the subject a bispecific antibody comprising a first antigen-binding region that binds a Vγ9Vδ2 T cell receptor (TCR) a second antigen-binding region that binds to EFGR. In some embodiments, the pancreatic cancer is pancreatic ductal adenocarcinoma.

Provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject an effective amount of a STAT inhibitor and an effective amount of an immune checkpoint inhibitor (e.g., a PD-1 inhibitor or a PD-L1 inhibitor).

Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.

Portable defibrillator (31; 41; 51; 61; 71) comprising: at least one treatment electrode (5); at least one sensor (4); at least one controller (2) connected to the at least one treatment electrode (5) and the at least one sensor (4); at least one response mechanism (6) wirelessly connected to the at least one controller (2), and wherein the at least one response mechanism (6) is activated by a patient (1) who uses the portable defibrillator (31; 41; 51; 61;71) is operable, characterized in that the at least one control (2) is configured: - in response to the detection of a patient condition requiring treatment via the at least one sensor (4), to provide a prompt issued by the portable defibrillator to the patient to elicit a response; - in response to the detection that the at least one response mechanism has not been activated, to provide treatment to the patient via the at least one treatment electrode; - in response to the detection that the patient has activated the at least one response mechanism, to prevent treatment of the patient via the at least one treatment electrode; and - to verify that it is the patient (1) who is wearing the portable defibrillator (31; 41; 51; 61;71) was, who activated the at least one response mechanism (6) by the at least one control (2) being designed to receive an input signal from the patient's body during activation of the at least one response mechanism, and to confirm, at least partially on the basis of the received input signal, that the patient (1), who is wearing the portable defibrillator (31; 41; 51; 61; 71), has activated the at least one response mechanism (6).

To provide a process for the use and preparation of fluorocyclopentenylcytosine.SOLUTION: The disclosed subject matter provides methods of using and kits comprising compounds of Formula (I): Formula (I) or hydrates, solvates or pharmaceutically acceptable salts thereof. The disclosed subject matter further provides methods for treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I), as well as processes for their preparation. The present invention also provides, among other things, an improved process for significantly reducing manufacturing costs by combining multiple steps and without isolating and purifying intermediate materials.SELECTED DRAWING: Figure 1